Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Apr 30;10(9):e30080.
doi: 10.1016/j.heliyon.2024.e30080. eCollection 2024 May 15.

Therapeutic implications of quercetin and its derived-products in COVID-19 protection and prophylactic

Wan-Yi Ho  1 , Zi-Han Shen  2 , Yijing Chen  3 , Ting-Hsu Chen  4 , XiaoLin Lu  5 , Yaw-Syan Fu  6   5
Affiliations
Review

Therapeutic implications of quercetin and its derived-products in COVID-19 protection and prophylactic

Wan-Yi Ho et al. Heliyon. .

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a novel human coronavirus, which has triggered a global pandemic of the coronavirus infectious disease 2019 (COVID-19). Outbreaks of emerging infectious diseases continue to challenge human health worldwide. The virus conquers human cells through the angiotensin-converting enzyme 2 receptor-driven pathway by mostly targeting the human respiratory tract. Quercetin is a natural flavonoid widely represented in the plant kingdom. Cumulative evidence has demonstrated that quercetin and its derivatives have various pharmacological properties including anti-cancer, anti-hypertension, anti-hyperlipidemia, anti-hyperglycemia, anti-microbial, antiviral, neuroprotective, and cardio-protective effects, because it is a potential treatment for severe inflammation and acute respiratory distress syndrome. Furthermore, it is the main life-threatening condition in patients with COVID-19. This article provides a comprehensive review of the primary literature on the predictable effectiveness of quercetin and its derivatives docked to multi-target of SARS-CoV-2 and host cells via in silico and some of validation through in vitro, in vivo, and clinically to fight SARS-CoV-2 infections, contribute to the reduction of inflammation, which suggests the preventive and therapeutic latency of quercetin and its derived-products against COVID-19 pandemic, multisystem inflammatory syndromes (MIS), and long-COVID.

Keywords: COVID-19; In silico; Long-COVID; MIS; Quercetin.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Figures

Image 1
Graphical abstract
Fig. 1
Fig. 1
The graphic portrays the genome of SARS-CoV-2.
Fig. 2
Fig. 2
The illustration depicts the structure of quercetin and its derivatives. All share the same core structure.
Fig. 3
Fig. 3
Quercetin and its derivatives docked on various domain or segment proteins of SRAS-CoV-2. Red indicates the dominated compounds. The black T bar present suppressed compounds. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)
Fig. 4
Fig. 4
The mediation of quercetin and its derivatives on (a) the inflammation and cytokine storm, (b). The expressions of inflammatory and interferon-stimulated genes and (c) the oxidative stress induced by SARS-CoV-2 infection.
figs1
figs1
See this image and copyright information in PMC

References

    1. Ciotti M., Angeletti S., Minieri M., et al. COVID-19 outbreak: an overview. Chemotherapy. 2019;64(5–6):215–223. doi: 10.1159/000507423. - DOI - PMC - PubMed
    1. Faiyazuddin M., Sophia A., Ashique S., et al. Virulence traits and novel drug delivery strategies for mucormycosis post-COVID-19: a comprehensive review. Front. Immunol. 2023;14 doi: 10.3389/fimmu.2023.1264502. - DOI - PMC - PubMed
    1. Hoffmann M., Kleine-Weber H., Schroeder S., et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181(2):271–280. doi: 10.1016/j.cell.2020.02.052. e8. - DOI - PMC - PubMed
    1. Kawasumi T., Takeno S., Ishino T., et al. Co-Expression and localization of angiotensin-converting enzyme-2 (ACE2) and the transmembrane serine protease 2 (TMPRSS2) in paranasal ciliated epithelium of patients with chronic Rhinosinusitis. Am. J. Rhinol. Allergy36. 2022;(3):313–322. doi: 10.1177/19458924211059639. - DOI - PubMed
    1. Cai J., Zhang H., Zhu K., et al. Risk of reinfection and severity with the predominant BA.5 Omicron subvariant China, from December 2022 to January 2023. Emerg. Microbes. Infect. 2024;13(1) doi: 10.1080/22221751.2023.2292071. - DOI - PMC - PubMed

LinkOut - more resources